Brokerages Set Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Price Target at $16.00

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) has been given an average rating of “Hold” by the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $16.00.

A number of research analysts have commented on NTHI shares. Wall Street Zen downgraded shares of Neonc Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Alliance Global Partners initiated coverage on shares of Neonc Technologies in a research note on Tuesday, May 19th. They issued a “buy” rating and a $13.00 target price on the stock. Maxim Group began coverage on shares of Neonc Technologies in a research note on Monday, May 18th. They issued a “buy” rating and a $20.00 target price on the stock. Weiss Ratings raised shares of Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Finally, BTIG Research reiterated a “buy” rating and issued a $15.00 price target on shares of Neonc Technologies in a research note on Tuesday.

Insider Buying and Selling

In other news, CEO Thomas C. Chen purchased 12,757 shares of the stock in a transaction dated Tuesday, August 18th. The stock was acquired at an average cost of $5.49 per share, for a total transaction of $70,035.93. Following the acquisition, the chief executive officer owned 13,705 shares of the company’s stock, valued at $75,240.45. The trade was a 1,345.68% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Amir F. Heshmatpour purchased 12,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $3.79 per share, for a total transaction of $45,480.00. Following the completion of the transaction, the chief executive officer owned 3,084,000 shares in the company, valued at approximately $11,688,360. This represents a 0.39% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 36,757 shares of company stock worth $178,486.

Institutional Trading of Neonc Technologies

Several institutional investors have recently added to or reduced their stakes in NTHI. Barclays PLC lifted its position in shares of Neonc Technologies by 5,314.8% in the 4th quarter. Barclays PLC now owns 9,151 shares of the company’s stock worth $76,000 after buying an additional 8,982 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Neonc Technologies during the 4th quarter valued at about $124,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Neonc Technologies during the 4th quarter valued at about $126,000. Royal Bank of Canada acquired a new stake in Neonc Technologies during the first quarter worth about $247,000. Finally, Global Retirement Partners LLC acquired a new stake in Neonc Technologies during the second quarter worth about $126,000.

Neonc Technologies Stock Performance

NTHI stock opened at $3.68 on Wednesday. The stock’s 50 day moving average is $4.07 and its two-hundred day moving average is $5.39. Neonc Technologies has a 52-week low of $3.01 and a 52-week high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.